A recombinant human broadly neutralizing monoclonal antibody that binds the HIV-1 Env gp120 CD4-binding site to block virus–CD4 interaction and entry; neutralizes diverse HIV-1 strains and can mediate Fc-dependent effector functions (ADCC/ADCP). The LS Fc mutations enhance FcRn binding and extend serum half-life.
Recombinant human broadly neutralizing monoclonal antibody that binds the HIV-1 Env gp120 CD4-binding site, blocking gp120–CD4 interaction and viral entry; neutralizes diverse HIV-1 strains and can engage Fc-dependent effector functions (ADCC/ADCP) against infected cells. LS Fc mutations enhance FcRn binding to extend serum half-life.
Binds gp120 on infected cells and engages FcγR-expressing effector cells to mediate ADCC/ADCP (and possibly CDC), leading to killing of target-expressing cells.
Monoclonal antibody linked to a cytotoxic payload to deliver chemotherapy directly to antigen-positive B cells.
A monoclonal antibody targets an antigen on malignant B cells, is internalized, and releases a linked cytotoxic payload inside the cell, causing targeted chemotherapy-induced cell death (e.g., microtubule or DNA damage) in antigen-positive B cells; may also retain Fc-mediated effector functions.
Antibody binds CD19 on B cells, is internalized, and releases a cytotoxic payload (e.g., microtubule or DNA-damaging agent) that kills the antigen-positive cell; Fc functions may add ADCC/CDC.
Monoclonal antibody linked to a cytotoxic payload to deliver chemotherapy directly to antigen-positive B cells.
A monoclonal antibody targets an antigen on malignant B cells, is internalized, and releases a linked cytotoxic payload inside the cell, causing targeted chemotherapy-induced cell death (e.g., microtubule or DNA damage) in antigen-positive B cells; may also retain Fc-mediated effector functions.
An anti-CD20 antibody-drug conjugate binds CD20 on B cells, is internalized, and releases a cytotoxic payload (e.g., microtubule or DNA-damaging agent) that kills antigen-positive cells; Fc effector functions may also contribute (ADCC/CDC).
Anti-CD20 monoclonal antibody that mediates complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and apoptosis of B cells.
Chimeric anti‑CD20 monoclonal antibody that binds CD20 on pre‑B and mature B cells and depletes them via complement‑dependent cytotoxicity, antibody‑dependent cellular cytotoxicity/phagocytosis, and induction of apoptosis.
Rituximab binds CD20 on B cells and kills them via complement-dependent cytotoxicity (MAC lysis), Fc-mediated ADCC/ADCP by immune effector cells, and induction of apoptosis.
Glycoengineered anti-CD20 monoclonal antibody that enhances ADCC and induces direct B-cell apoptosis.
Glycoengineered humanized type II anti-CD20 IgG1 that binds CD20 on B cells; afucosylated Fc increases affinity for FcgammaRIIIa on effector cells to enhance ADCC; also induces direct, caspase-independent B-cell apoptosis.
Obinutuzumab binds CD20 on B cells; its afucosylated Fc strongly engages FcγRIIIa on NK cells/macrophages to trigger ADCC/ADCP, and it also induces direct, caspase‑independent apoptosis of CD20+ B cells.